ARTICLE | Company News
Opko, Scripps Research Institute deal
March 19, 2012 7:00 AM UTC
The institute granted Opko exclusive, worldwide rights to develop and commercialize SR-3306. The c-jun N-terminal kinase (JNK) inhibitor is being developed to treat Parkinson's disease (PD). Details...